Tyler Bold

Tyler Bold, MD, PhD serves as Associate Professor in the Division of Infectious Diseases and International Medicine within the Department of Medicine at the University of Minnesota Medical School. He concurrently holds faculty appointments in the Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program and the Department of Medicine, establishing a multidisciplinary research presence spanning infectious disease pathogenesis, immunology, and host-pathogen interactions.

His research program integrates clinical infectious disease expertise with fundamental immunological investigation, focusing on tuberculosis host-directed immunotherapy, SARS-CoV-2 pathogenesis mechanisms, and macrophage biology in atherosclerosis. Key interests include T cell costimulation in granulomatous diseases, viral-microbiome interactions during respiratory infections, and diagnostic innovations for resource-limited settings. His work bridges basic science discovery with translational clinical applications, particularly in immunocompromised populations and complex infectious syndromes.

Analysis of his 15 most recent publications reveals dominant research trajectories in tuberculosis immunology (40% of articles), SARS-CoV-2 pathogenesis and therapeutics (35%), and atherosclerosis immunometabolism (15%), with emerging work on fungal infections in hematologic malignancies. The publications demonstrate consistent use of advanced techniques including single-cell resolution analysis, structural biology, and randomized clinical trials, reflecting both mechanistic depth and clinical relevance across infectious disease subspecialties.